UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 27,889 Shares of Glaukos Co. (NYSE:GKOS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 20.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 162,326 shares of the medical instruments supplier's stock after purchasing an additional 27,889 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.29% of Glaukos worth $24,339,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in GKOS. IFP Advisors Inc bought a new position in shares of Glaukos in the 4th quarter worth about $43,000. Asset Planning Inc purchased a new position in shares of Glaukos in the fourth quarter worth approximately $90,000. CoreCap Advisors LLC boosted its holdings in shares of Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 200 shares during the last quarter. Picton Mahoney Asset Management purchased a new position in Glaukos during the fourth quarter valued at approximately $125,000. Finally, SBI Securities Co. Ltd. purchased a new position in Glaukos during the fourth quarter valued at approximately $153,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GKOS shares. Mizuho reduced their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company lowered shares of Glaukos from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Piper Sandler reduced their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, April 15th. Truist Financial reiterated a "buy" rating and issued a $135.00 price target (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Finally, Stifel Nicolaus lowered their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $134.67.

Insider Transactions at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. This represents a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 5.80% of the company's stock.

Glaukos Price Performance

Shares of GKOS traded down $0.54 during mid-day trading on Friday, reaching $94.33. The company had a trading volume of 1,146,074 shares, compared to its average volume of 707,621. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company's 50-day moving average is $92.61 and its 200-day moving average is $122.91. The company has a market capitalization of $5.39 billion, a P/E ratio of -32.87 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same period last year, the company earned ($0.70) earnings per share. The company's revenue was up 24.6% on a year-over-year basis. On average, equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.